Cargando…

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations

BACKGROUND: The potentials of circulating tumour DNA (ctDNA) have been studied for non-invasive disease monitoring in patients with targetable mutations. However, the majority of cancer patients harbour no targetable mutations. A workflow including targeted next-generation sequencing (NGS) and dropl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demuth, Christina, Winther-Larsen, Anne, Madsen, Anne Tranberg, Meldgaard, Peter, Sorensen, Boe Sandahl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089565/ https://www.ncbi.nlm.nih.gov/pubmed/30123427 http://dx.doi.org/10.18632/oncotarget.25779

Ejemplares similares

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2017)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Day-to-day and within-day biological variation of cell-free DNA
por: Madsen, Anne Tranberg, et al.
Publicado: (2019)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
por: Winther-Larsen, Anne, et al.
Publicado: (2016)

Intra‐individual variation of circulating tumour DNA in lung cancer patients
por: Hojbjerg, Johanne A., et al.
Publicado: (2019)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)
por: Månsson, Christoffer Trier, et al.
Publicado: (2021)

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
por: Pedersen, Jesper Geert, et al.
Publicado: (2020)

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer
por: Lyskjær, Iben, et al.
Publicado: (2019)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
por: Dissing, Julie Gabe, et al.
Publicado: (2022)

Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer
por: Stensgaard, Simone, et al.
Publicado: (2023)

Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
por: Oversoe, Stine Karlsen, et al.
Publicado: (2021)

Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients
por: Trier Maansson, Christoffer, et al.
Publicado: (2023)

Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
por: Sorensen, Boe S, et al.
Publicado: (2014)

DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies
por: Maansson, Christoffer Trier, et al.
Publicado: (2023)

Gene Expression of the EGF System—a Prognostic Model in Non–Small Cell Lung Cancer Patients Without Activating EGFR Mutations()
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2016)

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
por: Gammelgaard, Kristine Raaby, et al.
Publicado: (2018)

Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients
por: Maansson, Christoffer T., et al.
Publicado: (2023)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Comparing single‐target and multitarget approaches for postoperative circulating tumour DNA detection in stage II–III colorectal cancer patients
por: Henriksen, Tenna Vesterman, et al.
Publicado: (2022)

Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
por: Palimaru, Irina, et al.
Publicado: (2013)

Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
por: Openshaw, Mark R., et al.
Publicado: (2020)

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel
por: Kisistók, Judit, et al.
Publicado: (2023)

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
por: Bønløkke, Sara, et al.
Publicado: (2022)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
por: Chang-Hao Tsao, Simon, et al.
Publicado: (2015)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2018)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma
por: Escudero, Laura, et al.
Publicado: (2020)

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
por: Weber, Britta, et al.
Publicado: (2014)

Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery
por: Ng, Sarah B., et al.
Publicado: (2017)

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
por: Clement, Michelle Simone, et al.
Publicado: (2020)

The In Vitro Stability of Circulating Tumour DNA
por: Henao Diaz, Emanuela, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_24u6chol0sgr3201emdqp4ucpv